The CONSENSE project is developing a new sensor technology suitable for measuring biomolecules important for monitoring disease status and treatment efficacy. A generic technology that enables the continuous measurement of a wide range of biomolecular parameters could revolutionise patient monitoring and enable truly personalised therapy with better outcomes.
CONSENSE brings together internationally leading pioneers in biomolecular switch engineering with research groups that have an excellent track record in biosensor development using advanced optical approaches, including two high-tech companies that have spun out from these groups. The consortium is completed by a strong network of partner industries and organisations, including four large medical technology companies, clinical experts, and six SMEs providing specific technical expertise and training.
The first international symposium on Continuous Real-Time Biomolecular Sensing
Follow up: 3rd CONSENSE week in Aarhus!
Hey everyone! We are very excited to share with you the highlights of the recent CONSENSE meeting in Aarhus,
CONSENSE celebrates the International Day of Women and Girls in Science
As the world celebrates the International Day of Women and Girls in Science 2024, the CONSENSE ITN proudly stands
First international symposium on Continuous Real-Time Biomolecular Sensing
The CONSENSE ITN is delighted to announce the first International Symposium on Continuous Real-Time Biomolecular Sensing, an event to